Larimar Therapeutics (LRMR) Other financing activities (2014 - 2020)

Larimar Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $8.4 million for Q2 2020.

• Quarterly Other financing activities rose 180.94% year-over-year to $8.4 million in Q2 2020, while the trailing twelve-month figure through Dec 2020 was $18.0 million (changed N/A YoY) and the FY2020 annual result came in at $18.0 million, down 7.22% from the prior year.
• Other financing activities was $8.4 million for Q2 2020 at Larimar Therapeutics, down from $9.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $9.9 million in Q3 2019 and bottomed at $40000.0 in Q1 2017.
• A 5-year average of $2.8 million and a median of $261000.0 in 2018 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2016 — Other financing activities tumbled 68.45% — and 2019, when it jumped 3977.46%.
• Larimar Therapeutics' Other financing activities stood at $165000.0 in 2016, then sank by 51.52% to $80000.0 in 2017, then surged by 2111.25% to $1.8 million in 2018, then surged by 462.41% to $9.9 million in 2019, then declined by 15.57% to $8.4 million in 2020.
• Business Quant data shows LRMR's Other financing activities at $8.4 million in Q2 2020, $9.6 million in Q1 2020, and $9.9 million in Q3 2019.